Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
https://twitter.com/bbi_solutions/status/1254743147801980929
Breakthrough not the right word to use.
Very early days. Earliest if all goes well - 3 months. Hoping to have something to go into production at that time.
I'm sitting on my hands. I bought NCYT at 45p and was in and out of that. Sometimes up and sometimes down. It was early days in the testing world and I didn't understand it half as much as I do now. That share was so volatile in the beginning it moved in both directions so quickly it made me doubt my investment decisions. I've learned a lot and this share is a keeper and I'm staying put. Let's see where we are this time next month. I think a lot of people will wish they had got in now. It really won't matter whether you are in at 60p or 85p in a month's time.
Avacta owns the intellectual property relating to the SARS-COV-2 Affimer reagents and retains all commercial rights. Avacta is in active discussion with other global diagnostic companies to develop Affimer-based COVID-19 antigen tests to increase high-throughput testing capacity on a world-wide scale.
Words that I like:
Owns the intellectual property
Retains all commercial rights
Active discussion
Global diagnostic companies
Increase high-throughput testing capacity
Worldwide scale
So, basically, I love the whole sentence!! Hahaha
Silkman, this is what you posted yesterday. I guess you sold out and want back in at a lower price today!#
"I have invested in ncyt and still stay invested but have also put some investment into odx and avtg. All these companies have the potential to go up significantly, but the way the AIM is , better to spread your risk."
NCYT is the only European based company on the list with CE-IVD approval.
genesig Real-Time PCR COVID-19 is used with ROCHE LightCycler 480 II PCR platform. Nice opportunity for ROCHE and NCYT.
The European demand for this product will be vast.
On 11–12 February 2020, WHO convened a forum to identify research gaps and priorities for COVID-19, co-hosted by GloPID-R. These priorities included the urgent need for access to accurate and standardized diagnostics for SARS-CoV-2 (the causative agent of COVID-19), which can be deployed in decentralized settings.
FIND is working closely with WHO to provide support on training, technical assistance, and capacity building to ensure access to accurate and high-quality diagnostic testing for SARS-CoV-2. Together with a third-party, referral laboratory, we are conducting an independent evaluation of multiple SARS-CoV-2 assays that are currently in use and will become available in the future.
https://www.finddx.org/covid-19/
As always DYOR
Agreed.
Also a nice bb. Some are just toxic! Happy to relax and enjoy the scenic journey with the roof down and the breeze in my hair. Better than the white knuckle rides of others!
By off radar, I mean compared to some of the other ‘darling’ shares. This is a great company and so much further ahead than the oft-chased others. It baffles me why some companies have higher mcs based on worse fundamentals.
So much better than GGP! Does anyone do their research these days?
“record-breaking results for Q4 2019 represent a fitting end to an operationally superb year.”
Tiny market cap considering!
Record gross quarterly income of US$12.78 million...
Great RNS!! Off radar!
The second in command at the US Centers for Disease Control and Prevention said with the help of the Chinese government, the agency was quickly able to develop a diagnostic test for the new coronavirus – but now the private sector should use its resources to scale up production of the tests.
The Company anticipates increased demand for its test for COVID-19 due to this extended use for clinical diagnosis.
The Group directly serves oncology, microbiology, haematology and serology markets as do its global partners, which include major corporates.
Unfortunately, I believe COVID-19 is going to be with us for some time yet. It has not yet shown us how it will play out. Diagnostic testing is going to be a big factor in combatting the spread until a vaccine is found.
NCYT got a CE-Mark for their product on Friday. It is only Thursday!